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he Baylor and Medical University of South Carolina Experience 1996 to 2007
alerian L. Fernandes, MD,* Christopher Nielsen, MD,* Sherif F. Nagueh, MD,†
my E. Herrin, MS,‡ Christine Slifka, RN,* Jennifer Franklin, RN,†
illiam H. Spencer III, MD*
harleston, South Carolina; and Houston, Texas
bjectives This study sought to determine the long-term outcome of alcohol septal ablation (ASA).
ackground There are inadequate data on the long-term outcome of ASA for symptomatic hyper-
rophic obstructive cardiomyopathy (HOCM).
ethods Six hundred and twenty-nine patients were enrolled consecutively (1996 to 2007) and
8.4% (n  619) underwent ASA with 92% follow-up in 2007. Evaluation included deaths, proce-
ural complications, pacemaker requirement, repeat ASA, and myectomy/valve surgery. Follow-up
arameters included angina (Canadian Cardiovascular Society score), dyspnea (New York Heart Asso-
iation functional class), exercise time, and echocardiographic indices (septal thickness, ejection frac-
ion, resting and provoked gradients).
esults Ethanol (2.6  1.0 ml) was injected into 1.3  0.5 septal arteries, inducing a septal infarct.
omplications included death 1% (n  6), permanent pacemaker requirement 8.2% (n  52), coro-
ary dissection 1.3% (n  8), and worsening mitral regurgitation 0.3% (n  2). The mean follow-up
as 4.6  2.5 years (range: 3 months to 10.2 years). During follow-up, New York Heart Association
unctional class decreased from 2.8  0.6 to 1.2  0.5 (p  0.001); Canadian Cardiovascular Society
ngina score decreased from 2.1  0.9 to 1.0  0 (p  0.001); and exercise time increased from 4.8
3.3 to 8.2  1.0 (p  0.001) min. The resting and provoked left ventricular outﬂow tract gradients
ecreased progressively (p  0.001) and remained low during follow-up. The septal thickness de-
reased from 2.1  0.5 cm to 1.0  0.1 cm (p  0.001) and the ejection fraction decreased from 68
9% to 62  3% (p  0.001). The survival estimates at 1, 5, and 8 years were 97%, 92%, and 89%,
espectively.
onclusions The initial beneﬁts of ASA were maintained during follow-up. (J Am Coll Cardiol Intv
008;1:561–70) © 2008 by the American College of Cardiology Foundation
rom the *Division of Cardiology, Medical University of South Carolina, Charleston, South Carolina; †Division of Cardiology,
ethodist-DeBakey Heart Center, Houston, Texas; and the ‡Department of Biostatistics, Bioinformatics and Epidemiology,
edical University of South Carolina, Charleston, South Carolina.anuscript received June 12, 2008; revised manuscript received July 21, 2008, accepted July 23, 2008.
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562amilial hypertrophic cardiomyopathy is a genetic disease
ith autosomal-dominant inheritance (1–3). Patients
ith this condition develop myocardial hypertrophy pri-
arily because of mutations of the genes encoding the
ardiac sarcomere. Patients with hypertrophic cardiomy-
pathy that is nonobstructive, although still at risk for
ardiovascular events, may remain asymptomatic until
ate in life (4,5). However, patients with left ventricular
utflow tract (LVOT) obstruction, referred to as hyper-
rophic obstructive cardiomyopathy (HOCM), are often
ymptomatic, and the severity of obstruction is an im-
ortant determinant of clinical outcome (6). Resting
VOT obstruction may be present in about one-third of
atients. Another one-third of symptomatic patients may
ot have a significant resting gradient, but develop severe
ynamic outflow tract obstruction with provocation (7).
Many strategies have been developed in an attempt to
elieve LVOT obstruction produced by the combination
of asymmetric septal hypertro-
phy and systolic anterior mo-
tion of the mitral valve (5).
Although medical therapy can
be effective in relieving symp-
toms, some patients remain se-
verely symptomatic. Data from
randomized trials showed a
predominant placebo effect
with dual-chamber pacing, and
cardiac pacing has found a lim-
ited role as a primary ther-
apy for medically refractory
HOCM (8,9).
For over 40 years, the stan-
dard for treating HOCM has
been surgical myectomy, which
involves resection of the hyper-
rophied septal muscle (10,11). Relief of obstruction is
oted in 90% of cases, with associated improvement in
ymptoms and outcomes. The surgical results from ter-
iary centers with experience have been very good (11),
ut widespread application is associated with significant
orbidity and mortality (12–19). The first description of
lcohol septal ablation was by Sigwart (20) in 1995, and
his procedure is now an established and readily available
ercutaneous treatment option with encouraging short-
nd mid-term results (21–25). However, because the
rocedure has been performed for just over 10 years,
esults of a systematic prospective long-term study are
acking. Accordingly, we report the outcome of 629
atients enrolled consecutively (November 1996 to
arch 2007) and prospectively followed up for symp-
oms, exercise performance, mortality, and echocardio-
bbreviations
nd Acronyms
SA  alcohol septal
blation
V  atrioventricular
CS  Canadian
ardiovascular Society
I  confidence interval
OCM  hypertrophic
bstructive cardiomyopathy
CD  implantable
ardioverter-defibrillator
VOT  left ventricular
utflow tract
YHA  New York Heart
ssociationraphic indices. fethods
he investigational protocol was approved by the institu-
ional review boards. All patients provided an informed
onsent form before participation.
ecruitment of patients and initial evaluation. Patients were
nrolled consecutively into the alcohol septal ablation study
rom November 1996 to August 2006 and followed up to
arch 2007. Criteria for enrollment were the following.
irst, patients were confirmed to have HOCM and were
till symptomatic despite medical therapy. Second, they had
esting echocardiogram/Doppler LVOT gradients30 mm
g at rest or a provoked gradient 60 mm Hg induced by
alsalva maneuver or exercise. Initially, dobutamine was
sed in patients (n  57) who were unable to exercise, but
t has not been used since 2001. Third, obstruction was
hown to be at the level of the outflow tract because of
ontact of the anterior mitral leaflet with the thickened
eptum. Fourth, the septal thickness was 1.6 cm with a
eptal–posterior wall ratio of 1.3:1. A complete history
nd physical examination were performed before the proce-
ure, along with a 2-dimensional Doppler/echocardiogram
ith provocation, if indicated.
ata collection and follow-up procedures. Patients were
valuated clinically after the procedure, and follow-up was
cheduled at 3 months, 1 year, and annually thereafter.
readmill exercise testing was performed using the Bruce
rotocol in patients who were able to exercise. In patients in
hom the LVOT gradient was induced only with provoca-
ion, follow-up gradients were assessed with the same
rovocation stimulus. Patients enrolled in the study with a
ignificant resting gradient did not undergo provocation
efore the procedure or in follow-up. Follow-up LVOT
radient in both groups was obtained by echocardiogram
oppler. Left ventricular ejection fraction was assessed by
he method of Quinones et al. (26).
lcohol septal ablation (ASA) procedure. Complete details
f the now-standard procedure have been reported previ-
usly (22). Briefly, a small balloon catheter is placed into an
ppropriate septal perforator artery, and subsequently abso-
ute alcohol is injected through the central lumen of the
nflated balloon, producing a localized area of injury. A
umber of modifications in the procedure have occurred
ver time, including the use of contrast echocardiography,
ofter guide wires, coaxial guiding catheters, a reduced
mount of ethanol, a slower injection rate, and smaller and
horter balloons. Acute technical success of the procedure in
he catheterization laboratory was defined as a decrease in
he LVOT gradient by at least 50% from baseline, deter-
ined either by Doppler/echocardiogram or invasive mea-
urements immediately after the procedure.
tatistical analysis. Continuous variables are presented as
ean SD. For continuous variables, serial changes duringollow-up were evaluated by repeated-measures ANOVA.
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563onferroni modification was used to assess differences at
ollow-up. Functional class changes were evaluated using
he Wilcoxon signed rank test. A p value 0.05 was
onsidered statistically significant. Cardiac events occurring
ithin 30 days of the procedure were considered
rocedure-related.
To determine the survival estimates, traditional Kaplan-
eier estimation was used. All-cause mortality was used for
he overall survival analysis. Individuals were either dead (of
ny cause) or were censored at the last date at which they
ere known to be alive. For event-free survival related to the
utcomes of the initial procedure, individuals had an event
procedural death, surgery, or repeat procedure) or were
ensored. In this case, death from any cause other than
rocedural death was treated as a censored event.
esults
ix hundred and twenty-nine patients were consecutively
nrolled in the study. The mean (SD) of follow-up time
based on overall survival) is 4.59 (2.47) years. The median
nd interquartile range (25th and 75th percentiles) is 4.49
2.75, 6.36) years, (range: 3 months to 10.2 years). Patients
ho could not come for follow-up visits at our centers were
ontacted by telephone and their functional status was
ssessed by a questionnaire or per their physician’s evalua-
ion. The Social Security Death Index database and a paid
nternet browser were used to track missing patients.
Of the 629 patients enrolled in the study, 579 (92%)
atients had follow-up data in 2007. Data for 50 of 629
atients (8%) were not available for 2007. Six of these 50
atients were foreign nationals. The other 44 patients were
ot represented as dead in the U.S. Social Security Death
ndex database. Thirty-two patients without 2007 follow-up
Table 1. Baseline Characteristics
Baseline All
Total
Age (yrs)
Male/female
Prior pacemaker/ICD
CCS angina score
NYHA score
Treadmill time (min)
Rest gradient (mm Hg) (n 
Provoked gradient (mm Hg) (n 
Septal thickness (cm)
Ejection fraction, %
Number of septal arteries injected
Amount of alcohol injected (ml)
Peak CK (U)
CCS Canadian Cardiovascular Society; CK creatine kinase; ICD implantable cardioverter-defiad at least 1 follow-up visit at 16  14 (mean  SD) ponths and a New York Heart Association (NYHA)
unctional class of 1.44  0.7 (mean  SD) when seen.
nly 18 (2.9%) patients were completely lost to follow-up
fter their ASA procedure. Attempted alcohol septal
blation was unsuccessful in 10 patients. Four patients opted
ut of follow-up, 25 patients underwent subsequent myec-
omy (includes 6 patients in whom ASA was not done), 11
atients had aortic or mitral valve surgery, and 51 pa-
ients died.
aseline characteristics. Baseline characteristics are shown
n Table 1. The ASA procedure was performed with
cute success in 619 patients (98.4%) (Table 2). The
ean age of patients in the study was 53.9  15 years
range: 13 to 90 years). The youngest patient was a
3-year-old Caucasian male patient with NYHA func-
ional class III symptoms who had recently suffered
ardiac arrest and was implanted with an implantable
ardioverter-defibrillator (ICD) and refused surgery.
here were 311 (49.5%) female patients. Most patients
ere receiving multiple medications for HOCM. There
ere 98 (15.6%) patients who had a prior pacemaker or
CD, and 6 had a prior myectomy. Five hundred and
hree patients (80%) had a mean resting gradient of 77 
1 mm Hg. There were 126 (20%) patients with no
ignificant resting gradient, but a mean provoked gradi-
nt of 74  33 mm Hg. Overall 1.3  0.5 septal arteries
ere injected with 2.6  1.0 ml ethanol per patient. The
ean value of peak creatine kinase was 1,243  713
nits/l. Most patients experienced burning chest discom-
ort during alcohol injection despite pre-medication with
eperidine or fentanyl and midazolam. No patient had
ustained ventricular fibrillation during alcohol injection.
n-hospital complications of the procedure. The major com-
ts at Entry No Follow-Up in 2007
29 50
 15.0 48 18
8/311 25/25
15.6%) 6 (12%)
 0.9 2.3 0.8
 0.6 2.9 0.6
 3.4 4.6 3
79%) 78 30 (n  41) (82%) 72 25
21%) 72 34 (n  9) (18%) 79 45
 0.5 2.2 0.5
 9 68 12
 0.5 1.4 0.6
 1.0 2.9 1.3
 716 1,285 615
; NYHA New York Heart Association.Patien
6
53.9
31
98 (
2.1
2.8
4.6
497) (
132) (
2.1
68
1.2
2.6
1,221lications of the procedure included death in 6 patients (1%)
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564Table 3), coronary dissection in 8 patients (1.3%), and
omplete heart block requiring permanent pacemaker in 52
atients (8.2%). Two patients (0.3%) required mitral valve
eplacement.
oronary dissections. The procedure was complicated by
oronary dissections in 8 patients. One patient had a
piral dissection complicated by ventricular fibrillation
nd arrest, which eventually led to the patient’s death
uring surgery. Another LAD dissection occurred before
lcohol injection and was referred directly to surgery. Five
f the remaining dissections were treated successfully by
oronary stents, and the other was left alone with no
eleterious consequences on follow-up. One of the dis-
ections was noted 10 days after the procedure, when the
atient had a repeat cardiac catheterization for chest pain
nd was stented uneventfully. The incidence of dissection
as disproportionately higher in women (7 female, 1
ale). As a result of these dissections, the procedure was
odified by using coaxial guide catheters and soft-tip
uide wires. Since then, no dissection has occurred in the
ast 400 patients.
ermanent pacemaker implantation. Permanent pacing
as needed in 52 patients after ASA for high-grade
trioventricular (AV) block or complete heart block. The
Table 2. Aborted Procedures
Causes of Failure
1 LAD dissection
2 Balloon could not be engaged in the septal perforator
3 Guide nonengagement with the left coronary ostium b
4 Tamponade developing because of LV biopsy
5 LAD dissection
6 Septal artery dissection
7 Left main dissection
8 Inadequate septal perforator arteries for ASA
9 Chest pain and ST-segment elevation in inferior leads b
10 Septal wire perforation with myocardial extravasation
ASA alcohol septal ablation; CABG coronary artery bypass graft surgery; LAD left anterior de
Table 3. Procedure-Related Deaths
Cause of Death
1 LAD dissection and ventricular ﬁbrillation during ASA, died during
surgery (acutely in the catheter laboratory)
2 Retroperitoneal bleeding from femoral vascular access (within 24 h of
septal ablation)
3 Acute septal perforation (VSD) in a patient with mild calciﬁc aortic
stenosis (within 24 h of septal ablation)
4 Left main dissection (acutely in the catheter laboratory)
5 Sudden death 10 days after ASA
6 Late inferior wall with RV infarction (10 days after ASA)mRV right ventricle; VSD ventricular septal defect; other abbreviations as in Table 2.ncidence of high-grade AV block necessitating perma-
ent pacemaker implantation in the initial 50 patients
as 28%. The incidence of AV block decreased signifi-
antly after the procedure was modified by slower injec-
ion of smaller amounts of ethanol per septal perforator
rtery and the use of myocardial contrast echocardiogra-
hy. In the subsequent 579 patients, the pacemaker
equirement rate was 6.5%, yielding a net rate of perma-
ent AV sequential pacing of 8.2% in the entire cohort of
29 patients. Excluding patients with a pre-existing
acemaker or ICD, the new pacemaker requirement
ttributable to high-grade AV block was 9.7%.
itral valve replacement. Periprocedural mitral regurgita-
ion occurred in 2 patients who required mitral valve
eplacement. This was thought to be because of suben-
ocardial ischemia during guide catheter manipulation.
ollow-up results, 1996 to 2007. EFFECT OF ALCOHOL SEP-
AL ABLATION ON SYMPTOMS AND EXERCISE PERFOR-
ANCE. All patients were symptomatic at presentation,
ith a mean baseline NYHA score of 2.8 0.6 for dyspnea.
ignificant improvement in the NYHA functional class
as seen at 3 months (NYHA score 1.4  0.6), after which
he initial benefit was maintained (Fig. 1). After 5 years,
86% (n  121) of patients available for evaluation were in
YHA functional class 1.
The CCS angina score at baseline was 2.1 0.9, which
mproved to 1.2  0.5 at 3 months, and remained fairly
table thereafter. Before ASA, 29% of patients were angina-
ree compared with 87% at 3 months and 92% (n  121)
t 5 years and thereafter.
Objectively, the treadmill exercise duration increased
rogressively from 4.9  3.4 min at baseline to 7.5  1.0
in for those tested at years 1 to 5.
FFECT OF ALCOHOL SEPTAL ABLATION ON LVOT GRADI-
NT. A resting gradient 30 mm Hg was present in 503
atients at baseline (Fig. 2). The mean resting gradient at
aseline was 77  31 mm Hg, which decreased to 26  27
Outcome
Died at surgery
Elective myectomy
of tortuosity Medical therapy
Emergent surgery and myectomy
Emergent CABG and myectomy
Elective myectomy
Died after emergent CABG and myectomy
Elective myectomy
ASA Medical therapy
Successful ASA later
g artery; LV left ventricle.artery
ecause
eforem Hg at 3 months, 20  24 mm Hg at 1 year, and
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565ontinued to decline yearly and was 10 mm Hg in those
ested after 5 years.
There were 126 symptomatic patients with a resting
radient 30 mm Hg, but with a significant provoked
radient. The baseline-provoked gradient of 74  33 mm
g decreased after ASA to 37  34 mm Hg at 3 months,
2  30 mm Hg at 1 year, and remained 10 mm Hg in
hose tested after 5 years.
FFECT OF ALCOHOL ABLATION ON SEPTAL THICKNESS
ND VENTRICULAR FUNCTION. Basal septal thickness mea-
ured at the site of the ablation decreased significantly from
.1  0.5 cm to 1.6  0.4 cm at 3 months, and 1.5  0.4
m at 1 year (Fig. 3). Thereafter, the mean septal thickness
t the site of ablation showed a gradual thinning over the
ollow-up period. Despite significant thinning of the sep-
um in some patients, no ventricular septal defects or
neurysms were noted during the follow-up period.
Average left ventricular ejection fraction was 68  9% at
aseline, and decreased to 65  9% at 3 months, but
emained mostly in the 60% to 65% range throughout the
ollow-up period (Fig. 4). Congestive heart failure caused by
ystolic dysfunction was not observed. Congestive heart
ailure during follow-up was attributable to diastolic
ysfunction.
epeat ASA and other procedures. A total of 91 repeat
SA procedures were needed in 81 patients (14%) for
Figure 1. NYHA/CCS Score (Subjective) and Treadmill Exercise Time (Obje
There was marked early improvement of heart failure symptoms (New York Heart Ass
months, and this improvement persisted during follow-up. This also correlated with imersistence or recurrence of symptoms, along with dy- pamic obstruction. An ASA was performed 4 times in 1
atient, 3 times in 4 patients, and twice in 76 patients.
uccess was related to the availability of additional target
eptal perforator arteries that were amenable for ablation.
ost patients with repeat procedures had a successful
eduction of the gradient and relief of symptoms
hroughout follow-up (94% success rate).
Twenty-five patients (includes 6 patients in whom the
SA was aborted) with persistent symptoms and residual
radients underwent surgical myectomy. In addition, 7
atients underwent mitral valve replacement, and 4 un-
erwent aortic valve replacement during follow-up. Four
atients had worsening mitral regurgitation during
ollow-up (2 of these 4 patients had worsening mitral
egurgitation periprocedurally. The other 2 patients de-
eloped flail mitral leaflets on longer follow-up requiring
urgery. The remaining 3 patients underwent surgery
lsewhere and the cause of the mitral regurgitation is
nknown. Two patients developed severe calcific aortic
tenosis at 5-year follow up, and were referred by us for
alve replacement. The other valve surgeries were recom-
ended by the referring cardiologist, and were performed
t the referring institution or at another center. There
ere 8 post-operative deaths.
ortality. There were 51 deaths over this 10-year follow-up
) Parameters During Follow-Up After ASA
n [NYHA] score) and angina (Canadian Cardiovascular Society [CCS] score) at 3
ment in treadmill exercise time. ASA  alcohol septal ablation; BL  baseline.ctive
ociatioeriod (Table 4). There were 24 deaths of cardiac origin, 21
n
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566oncardiac deaths, and 6 deaths attributable to unknown
auses. The mean age at death was 67  14 years (range: 27
o 88 years). At the time of death, 6 patients (12%) were
50 years old, and 27 patients (53%) were 70 years old.
Figure 2. Resting and Provoked LVOT Gradients During Follow-Up After AS
There is a marked reduction in both resting and provoked left ventricular outﬂ
further reduction of gradients until 5 years, and this improvement persisted du
Figure 3. Septal Thickness During Follow-Up After ASAThere was marked reduction of septal thickness at 3 months after alcohol septal ablationhe older patients had significant comorbidities. There
ere 6 procedure-related deaths, of which 2 were
issection-related and 1 was caused by an acute ventricular
eptal defect. One patient died because of retroperitoneal
act (LVOT) gradients at 3 months after alcohol septal ablation (ASA). There is
ollow-up. BL  baseline.A
ow trand further gradual reduction during follow-up. Abbreviations as in Figure 1.
b
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remained in normal range during follow-up. Abbreviations as in Figure 1.
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567leeding. There were 2 deaths at 10 days, 1 because of an
rrhythmia and the other because of late inferior wall and
ight ventricular infarction caused by a right coronary ar-
ery clot.
Of the 629 individuals, 611 had sufficient follow-up
nformation regarding overall survival and could be included
n the Kaplan-Meier analysis (Fig. 5) (18 patients were not
vailable for follow-up after the ASA procedure). The
-year survival estimate (95% confidence interval [CI]) for
ll-cause mortality is 0.97 (95% CI: 0.95 to 0.98). After the
-year mark, 565 individuals were still at risk of death and
ere being followed up in the study. The 5-year survival
stimate is 0.92 (95% CI: 0.90 to 0.94), with 272 individuals
till at risk for death. At the 8-year time point, the survival
stimate is 0.89 (95% CI: 0.86 to 0.92), with 130 individuals
t risk. The last event occurred at 8.36 years, so no further
urvival estimates are reported.
Figure 4. Ejection Fraction During Follow-Up After ASA
The ejection fraction, which was hyperdynamic at baseline, declined gradually but
Table 4. Mortality Data (51 Deaths)
Cardiac Deaths (n  24) Noncardiac Deaths (n  21)
Procedure related, n  6 Lung disease, n  7
Post-operative, n  8 Infection and sepsis, n  4
CHF (EF 60%), n  3 Cancer, n  3
SCD, n  7 CVA, n  4
Other causes, n  3
There were 6 deaths with unknown causes.
CHF congestive heart failure; CVA cerebrovascular accident; EF ejection fraction; SCDsudden cardiac death.Figure 5. Kaplan-Meier All-Cause Mortality
The 1-year survival estimate for all-cause mortality is 0.97 (95% conﬁ-
dence interval [CI]: 0.95 to 0.98). After the 1-year mark, 565 individuals
were still at risk for death and were being followed up in the study. The
5-year survival estimate is 0.92 (95% CI: 0.90 to 0.94), with 272 individu-
als still at risk for death. At the 8-year time point, the survival estimate
is 0.89 (95% CI: 0.86 to 0.92), with 130 individuals at risk. Pts 
patients.
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568vent-free survival. Event-free survival, freedom from pro-
edural death, cardiac surgery, and repeat alcohol septal
blation procedure are shown in the Kaplan-Meier curve
Fig. 6). Six hundred and twenty-seven subjects were
ncluded in the analysis of event-free survival. Procedural
eaths, repeat procedures, and surgeries (myectomy, mitral/
ortic valve surgery) were all included as events in this
nalysis. Deaths from causes other than procedural deaths
ere censored at the time of death. Of the 627 individuals
sed in this analysis, 113 had an event. The 1-year survival
stimate and 95% CI is 0.88 (95% CI: 0.85 to 0.91), with
09 patients at risk at the 1-year time point. The 5-year
urvival estimate and confidence interval is 0.80 (95% CI:
.77 to 0.83), with 249 patients at risk.
iscussion
his report represents the largest number of patients en-
olled consecutively as candidates for ASA. The procedure
as feasible in most patients. Complications of the proce-
ure included primarily complete heart block and coronary
issections. Importantly, procedural modifications markedly
educed coronary dissections, and reduced the incidence of
omplete heart block to 10%. Alcohol septal ablation
esulted in significant clinical and hemodynamic improve-
Figure 6. Kaplan-Meier Event-Free Survival
Procedural deaths, repeat procedures, and surgeries (myectomy, mitral/
aortic valve surgery) were all included as events in this analysis. Deaths
from causes other than procedural deaths were censored at the time of
death. Of the 627 individuals in this analysis, 113 had an event. The 1-year
survival estimate and 95% conﬁdence interval (CI) is 0.88 (95% CI: 0.85 to
0.91), with 509 patients at risk at the 1-year time point. The 5-year survival
estimate and conﬁdence interval is 0.80 (95% CI: 0.77 to 0.83), with 249
patients at risk. Pts  patients.ent in the vast majority. The LVOT gradient, both resting Tnd provoked, was markedly reduced at 3 months and
ontinued to decrease during the 10-year period. The
VOT gradient reduction was accompanied by a significant
eduction in dyspnea and angina, as well as improvement in
xercise tolerance, all of which were sustained throughout
he follow-up period.
easibility. There were 10 cases of procedure failure, 4 were
aused by coronary dissections, all of which occurred early,
nd since the modification of the procedure with coaxial
uide catheters and soft guide wires, none have occurred.
wo early procedures that were aborted for technical rea-
ons could probably have been performed now because of
maller balloons and operator experience.
epeat ASA. There were 91 repeat procedures in 81 pa-
ients. The reasons for this 14% incidence of repeat proce-
ures are several. First, because this cohort starts with the
eginning of the alcohol ablation experience, it is in part
elated to the steep learning curve. Second, the determinants
f acute success in the laboratory are at best inexact and
herefore may not always predict long-term success. More
mportantly, we were successful in most (94%) of the repeat
rocedures.
ortality. During this 10-year follow-up period, there were
1 deaths, of which 24 were cardiac deaths. Six deaths were
rocedure-related, and 7 were sudden cardiac deaths. Post-
perative deaths accounted for 8 patients (of 36 patients
ho had myectomy/mitral valve/aortic valve surgery). These
patients were elderly women (mean age 67.5 13.9 years)
ith significant comorbidities. Only 2 of these patients who
nderwent valve replacement or myectomy surgery died
nder our care post-operatively.
There were 3 deaths of congestive heart failure. None of
he heart failure deaths were caused by systolic dysfunction.
number of elderly patients had significant comorbidities
nd died of noncardiac causes or unknown causes.
omparison with surgical myectomy. There is ongoing con-
roversy regarding the outcome and efficacy of ASA as
ompared with myectomy for the treatment of symptomatic
OCM (27,28). Several nonrandomized retrospective re-
orts have been published (29–33), but there are no
rospective, randomized trials of the 2 procedures.
Concern has been expressed that the septal scar resulting
rom ASA would create a milieu for the generation of
alignant ventricular arrhythmias and resultant sudden
ardiac death (34). Yet, the low incidence of known sudden
ardiac death during the follow-up period seems to negate
hese concerns. However, it is to be noted that 8% (n  50)
f patients were lost to final follow-up in 2007. It is
eassuring that 44 of these patients who were U.S. nationals
ere not represented as dead in the Social Security death
ndex database.
The 1-year (97%), 5-year (92%) and 8-year (89%) sur-
ival are similar to the survival after surgical myectomy from
oronto General Hospital (35) (n 338), and Mayo Clinic
(
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56936) (n  289), which was 98%, 95% to 96%, and 83% at 1,
, and 10 years, respectively. The surgical series had a longer
ollow-up duration (Toronto General Hospital: 7.7  5.7
ears, Mayo Clinic: 5.8 4 years) compared with 4.6 2.5
ears in this alcohol septal ablation cohort. This patient
ohort was older (53.9  15 years) than the Toronto
eneral Hospital (47  14 years) or Mayo Clinic (45.3 
9 years) cohorts, yet the long-term survival was similar.
We (37) and others (38) have shown that the relief of
VOT obstruction with ASA is associated with a signifi-
ant regression of left ventricular hypertrophy. Because the
xtent of hypertrophy (5) in HOCM as well as LVOT
bstruction (6) has been shown to be independent risk
actors for cardiac death, it is possible that regression of
ypertrophy and gradient reduction more than offset the
utative risk attributable to the localized septal infarction.
tudy limitations. This is a prospective, nonrandomized
tudy that is limited by the lack of a control/comparison
roup and a paucity of objective follow-up data after 5 years.
lso, dobutamine provocation, used initially, is no longer
sed because of a lack of specificity. The wide geographic
istribution of patients within the U.S. and abroad made it
ifficult to get some patients to return for follow-up at our
enter, which could have affected the outcomes.
onclusions
he present study shows that ASA is a safe and efficacious
reatment for symptomatic HOCM. An ASA can be
erformed in most patients with a high success rate. This
eport shows that successful alcohol ablation results in a
ustained clinical and hemodynamic improvement.
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